Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,561 to 3,580 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| IBD Cases With Mental Health Condition vs IBD Cases Without Mental Health Condition (Reference Group): Stream 2: Relative Risk of Low Mood (Emotional Function) | 63 of 295 119 of 1,648 | 14.1 points 9.6 to 19.3 | 1,943 | NCT05206734 Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health |
| IBD Cases With Mental Health Condition vs IBD Cases Without Mental Health Condition (Reference Group): Stream 2: Relative Risk of Sleep Disturbance (Quality of Life Indicator) | 26 of 295 83 of 1,648 | 3.8 points 0.8 to 7.7 | 1,943 | NCT05206734 Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health |
| Fluzone Quadrivalent Vaccine, 0.25-mL vs Fluzone Quadrivalent Vaccine, 0.5-mL: serious adverse events | 5 of 949 5 of 992 | 0.0 points -0.7 to 0.8 | 1,941 | NCT02915302 Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children |
| SOC Arm vs Enhanced Arm: Number of Participants Undergoing HIV Testing Within 12 Months | 361 of 918 552 of 1,021 | -14.7 points -19.1 to -10.3 | 1,939 | NCT04429061 Reaching 90 90 90 in Adolescents in Zambia: Using All Our SKILLZ |
| Intervention Arm vs Control Arm: deaths from any cause | 9 of 969 12 of 969 | -0.3 points -1.3 to 0.7 | 1,938 | NCT01737281 Proactive Outreach for Smokers in VA Mental Health |
| Intervention Arm vs Control Arm: serious adverse events | 39 of 969 28 of 969 | 1.1 points -0.5 to 2.8 | 1,938 | NCT01737281 Proactive Outreach for Smokers in VA Mental Health |
| Message-based Outreach Intervention (MBI) for Survivors vs Standard Outreach for Survivors: Number of Survivors Using Website Access Code | 147 of 969 202 of 969 | -5.7 points -9.1 to -2.3 | 1,938 | NCT04927013 Connecting Families to Overcome Ovarian Cancer |
| Roflumilast 500 µg vs Placebo: serious adverse events | 249 of 968 285 of 967 | -3.7 points -7.7 to 0.2 | 1,935 | NCT01329029 Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS) |
| TC Arm vs TAC Arm: deaths from any cause | 110 of 969 88 of 965 | 2.2 points -0.5 to 4.9 | 1,934 | NCT00493870 TAC Versus TC for Adjuvant Breast Cancer |
| TC Arm vs TAC Arm: serious adverse events | 264 of 969 330 of 965 | -7.0 points -11.0 to -2.8 | 1,934 | NCT00493870 TAC Versus TC for Adjuvant Breast Cancer |
| Arm A: FAC vs Arm B: FAC-wP: Overall Survival (OS) Event | 40 of 974 31 of 951 | 0.8 points -0.9 to 2.6 | 1,925 | NCT00129389 FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients |
| Arm A: FAC vs Arm B: FAC-wP: deaths from any cause | 40 of 974 31 of 951 | 0.8 points -0.9 to 2.6 | 1,925 | NCT00129389 FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients |
| Arm A: FAC vs Arm B: FAC-wP: Disease-free Survival (DFS) Event | 98 of 974 71 of 951 | 2.6 points 0.1 to 5.1 | 1,925 | NCT00129389 FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients |
| Arm A: FAC vs Arm B: FAC-wP: serious adverse events | 60 of 974 61 of 951 | -0.3 points -2.5 to 1.9 | 1,925 | NCT00129389 FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients |
| BioNIR vs Resolute: deaths from any cause | 5 of 958 2 of 961 | 0.3 points -0.3 to 1.0 | 1,919 | NCT01995487 Study of BioNIR Drug Eluting Stent System in Coronary Stenosis |
| Transdisciplinary Approach vs Multidisciplinary Approach: Wandering | 38 of 521 98 of 1,393 | 0.3 points -2.2 to 3.1 | 1,914 | NCT03442322 Optimizing Care for Patients With Dementia |
| Transdisciplinary Approach vs Multidisciplinary Approach: Rejection of Care | 59 of 521 217 of 1,393 | -4.3 points -7.4 to -0.7 | 1,914 | NCT03442322 Optimizing Care for Patients With Dementia |
| Arm I vs Arm II: deaths from any cause | 100 of 959 100 of 954 | -0.1 points -2.8 to 2.7 | 1,913 | NCT00754845 Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy |
| Arm I vs Arm II: serious adverse events | 15 of 959 19 of 954 | -0.4 points -1.7 to 0.8 | 1,913 | NCT00754845 Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy |
| Transdisciplinary Approach vs Multidisciplinary Approach: Behavioral Symptoms | 68 of 521 232 of 1,392 | -3.6 points -6.9 to 0.1 | 1,913 | NCT03442322 Optimizing Care for Patients With Dementia |
Code
curl "https://conductscience.org/api/comparisons/v1?page=179"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=179
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT05206734-1a8fcd84",
"title": "IBD Cases With Mental Health Condition vs IBD Cases Without Mental Health Condition (Reference Group): Stream 2: Relative Risk of Low Mood (Emotional Function)",
"summary": "63 of 295 against 119 of 1648; risk difference 14.1 points, 95% interval 9.6 to 19.3; NCT05206734, Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health",
"record": "/library/comparisons/NCT05206734-1a8fcd84",
"nct_id": "NCT05206734",
"kind": "outcome",
"participants": 1943,
"risk_difference": {
"value": 0.14135058416982063,
"lower": 0.09634498259237718,
"upper": 0.19294668666923143
},
"group_1": "63 of 295",
"group_2": "119 of 1,648",
"difference": "14.1 points",
"interval": "9.6 to 19.3",
"trial_title": "Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health"
},
{
"id": "NCT05206734-28de7d4d",
"title": "IBD Cases With Mental Health Condition vs IBD Cases Without Mental Health Condition (Reference Group): Stream 2: Relative Risk of Sleep Disturbance (Quality of Life Indicator)",
"summary": "26 of 295 against 83 of 1648; risk difference 3.8 points, 95% interval 0.8 to 7.7; NCT05206734, Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health",
"record": "/library/comparisons/NCT05206734-28de7d4d",
"nct_id": "NCT05206734",
"kind": "outcome",
"participants": 1943,
"risk_difference": {
"value": 0.03777151555043607,
"lower": 0.008110077645064606,
"upper": 0.07682683008585464
},
"group_1": "26 of 295",
"group_2": "83 of 1,648",
"difference": "3.8 points",
"interval": "0.8 to 7.7",
"trial_title": "Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=180",
"request_id": "WjYpXe7r83lHXZD_"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant